CMS concentrates on innovative products that are global first-in-class or with the best efficacy, safety or cost-effectiveness in the class due to their innovative formulations or drug delivery systems. Through industrial investment in and/or establishment of joint venture with global innovative R&D companies and strategic cooperation with globally leading pharmas, the Group has established an innovative pipeline with relatively high innovation level, good market potential and competitive differentiation advantages.

CMS enriched the dermatology line and entered the medical aesthetic filed through acquisition of Luqa Ventures, a dermatology specialty company. The Group will continuously utilize its domestic and overseas channel resources to deploy professional dermatological products and cutting-edge medical aesthetic solutions globally to build a comprehensive skin health product matrix consisting of prescription medicines, medical devices, medical aesthetic solutions and dermatology-grade skin care products; in the meantime, the Group will leverage its extensive network resources in the dermatology, and integrate hospital, medical institution, retail and internet channels to build a leading skin management and high-end medical aesthetic brand in China, with first-rate competitiveness, and fulfill the increasingly diverse needs for skin management and beauty of Chinese consumers.

Capitalizing on its strengths such as overseas channel resources accumulated for more than two decades, good reputation, unique product evaluation system, responsive global supply chain system, and strong promotion network, CMS stringently selects functional quality healthcare products with unique ingredients globally according to medical concept and high standards, and supplies the products to Mainland China through cross-border e-commerce platforms, so as to provide consumers with healthy lives.